ACA
AGIO icon

Avoro Capital Advisors’s Agios Pharmaceuticals AGIO Stock Holding History

Avoro Capital Advisors’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-150,000
Closed -$7.92M – 44
2016
Q3 		$7.92M Buy
+150,000
New +$6.53M 1.39% 22

Other funds holding AGIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Avoro Capital Advisors's AGIO Position: Q4 2016 in Review

Avoro Capital Advisors sold out of Agios Pharmaceuticals (AGIO) in Q4 2016, closing a stake of 150,000 shares — an estimated $7.92M sold.

Avoro Capital Advisors first reported a position in AGIO in Q3 2016 and held it in 1 quarter. The position peaked at $7.92M in Q3 2016. 161 funds tracked by Wall St. Rank hold AGIO as of Q4 2016.

  • Avoro Capital Advisors reported no remaining Agios Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Avoro Capital Advisors sold 150,000 Agios Pharmaceuticals shares in Q4 2016, an estimated $7.92M.
  • Avoro Capital Advisors first reported a position in Agios Pharmaceuticals in Q3 2016 and held it in 1 quarter.
  • Avoro Capital Advisors's Agios Pharmaceuticals position peaked at $7.92M in Q3 2016.
  • 161 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q4 2016.

Based on Avoro Capital Advisors's 13F filing for Q4 2016, filed 14 Feb 2017.